2 results about "Pulmonary Macrophages" patented technology

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

This application relates to the field of biomedical technology, specifically disclosing a siRNA lipid nanoparticle delivery system for treating lung infections, its preparation method, and its application. This application utilizes M2 macrophage-targeting lipid nanoparticles (LNPs) as carriers, delivering WTAP-targeting siRNA to alveolar macrophages via intratracheal instillation. This achieves specific intervention in the m6A methylation modification of alveolar macrophages, thereby actively enhancing the phagocytic clearance, inflammation regulation, and bactericidal functions of AMs, ultimately improving the host's defense against lung bacterial infections (especially drug-resistant bacterial infections).